Total Payments
$716,039
2024 Payments
$63,420
Companies
34
Transactions
274
Payment Breakdown by Category
Consulting$235,937 (33.0%)
Research$191,080 (26.7%)
Other$179,862 (25.1%)
Royalty/License$78,055 (10.9%)
Travel$25,814 (3.6%)
Food & Beverage$5,244 (0.7%)
Education$48.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $235,937 | 35 | 33.0% |
| Unspecified | $191,080 | 26 | 26.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $179,862 | 50 | 25.1% |
| Royalty or License | $78,055 | 19 | 10.9% |
| Travel and Lodging | $25,814 | 63 | 3.6% |
| Food and Beverage | $5,244 | 80 | 0.7% |
| Education | $48.00 | 1 | 0.0% |
Payments by Type
General
$524,960
248 transactions
Research
$191,080
26 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sage Therapeutics, Inc. | $153,974 | 41 | $0 (2024) |
| Janssen Research & Development, LLC | $133,896 | 21 | $0 (2024) |
| Biogen, Inc. | $64,158 | 6 | $0 (2022) |
| ITI, Inc. | $52,500 | 5 | $0 (2023) |
| Eisai Inc. | $34,611 | 44 | $0 (2021) |
| AbbVie Inc. | $33,503 | 5 | $0 (2023) |
| LivaNova USA, Inc. | $31,000 | 2 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $24,088 | 37 | $0 (2020) |
| H. Lundbeck A S | $22,734 | 4 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $22,307 | 41 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $63,420 | 7 | Sage Therapeutics, Inc. ($40,000) |
| 2023 | $95,889 | 26 | Sage Therapeutics, Inc. ($43,664) |
| 2022 | $262,359 | 38 | Janssen Research & Development, LLC ($108,120) |
| 2021 | $26,635 | 22 | Biohaven Pharmaceuticals, Inc. ($8,150) |
| 2020 | $102,276 | 30 | Biogen, Inc. ($33,756) |
| 2019 | $118,724 | 89 | H. Lundbeck A S ($22,734) |
| 2018 | $4,505 | 12 | Sunovion Pharmaceuticals Inc. ($4,323) |
| 2017 | $42,231 | 50 | SANOFI-AVENTIS U.S. LLC ($15,106) |
All Payment Transactions
274 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | USWM, LLC | Lucemyra (Drug) | Consulting Fee | Cash or cash equivalent | $480.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/08/2024 | Janssen Research & Development, LLC | — | Royalty or License | Cash or cash equivalent | $4,750.00 | General |
| 04/04/2024 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $10,000.00 | General |
| 02/05/2024 | Orion Corporation | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 02/01/2024 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $30,000.00 | General |
| 01/23/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Royalty or License | Cash or cash equivalent | $7,520.00 | General |
| Category: PSYCHIATRY | ||||||
| 01/03/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Royalty or License | Cash or cash equivalent | $7,520.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/30/2023 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $5,550.00 | General |
| 11/24/2023 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $450.00 | General |
| 06/30/2023 | Sage Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $1,542.22 | General |
| 06/30/2023 | Sage Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $176.50 | General |
| 06/30/2023 | Sage Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $26.09 | General |
| 06/29/2023 | Sage Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $318.10 | General |
| 06/29/2023 | Sage Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $103.41 | General |
| 06/29/2023 | Sage Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $100.48 | General |
| 06/29/2023 | Sage Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $99.17 | General |
| 06/29/2023 | Sage Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $73.73 | General |
| 06/28/2023 | Sage Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $229.75 | General |
| 06/28/2023 | Sage Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $144.63 | General |
| 06/22/2023 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $19,535.00 | General |
| 06/22/2023 | Sage Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $465.00 | General |
| 04/11/2023 | ITI, Inc. | CAPLYTA (Drug) | Consulting Fee | Cash or cash equivalent | $2,300.00 | General |
| Category: PSYCHIATRY | ||||||
| 03/14/2023 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,680.00 | General |
| Category: INSOMNIA | ||||||
| 03/09/2023 | Sage Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $712.20 | General |
| 03/09/2023 | Sage Therapeutics, Inc. | — | Travel and Lodging | In-kind items and services | $72.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis | Biogen, Inc. | $54,571 | 2 |
| A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression | LivaNova USA, Inc. | $31,000 | 2 |
| EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN DELAYED SLEEP-WAKE PHASE DISORDER (DSWPD) | Vanda Pharmaceuticals Inc. | $19,877 | 3 |
| Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia | ABBVIE INC. | $15,210 | 1 |
| Clinical Study 18498A | H. Lundbeck A S | $15,000 | 1 |
| Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World Setting | AbbVie Inc. | $12,270 | 1 |
| A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema | Mylan Inc. | $11,070 | 1 |
| An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension | Biogen, Inc. | $8,620 | 1 |
| A MULTI-CENTER, RANDOMIZED, CONTROLLED TRIAL TO EVALUATE THE EFFECTIVENESS OF A DIGITAL THERAPEUTIC (CT-152) AS ADJUNCTIVE THERAPY IN ADULT SUBJECTS DIAGNOSED WITH MAJOR DEPRESSIVE DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $5,790 | 1 |
| Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia | H. Lundbeck A S | $3,734 | 1 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | Teva Pharmaceuticals USA, Inc. | $3,690 | 1 |
| A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder | Allergan Inc. | $2,748 | 7 |
| A randomized, double-blind, placebo-controlled, parallel groups clinical trial to assess the safety and efficacy of Lactobacillus paracasei Lpc-37 to modulate psychological stress | E.R. Squibb & Sons, L.L.C. | $2,000 | 1 |
| Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder GAD RECONNECT | H. Lundbeck A S | $2,000 | 1 |
| Vortioxetine in Patients With Depression and Early Dementia MEMORY | H. Lundbeck A S | $2,000 | 1 |
| Lofexidine Clinical Adult Taper Study | US WorldMeds, LLC | $1,500 | 1 |
About Dr. David Sheehan, MD
Dr. David Sheehan, MD is a Psychiatry healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437263365.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Sheehan, MD has received a total of $716,039 in payments from pharmaceutical and medical device companies, with $63,420 received in 2024. These payments were reported across 274 transactions from 34 companies. The most common payment nature is "Consulting Fee" ($235,937).
Ad
Practice Information
- Specialty Psychiatry
- Location Tampa, FL
- Active Since 08/18/2006
- Last Updated 02/03/2010
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1437263365
Products in Payments
- SPRAVATO (Drug) $146,056
- CAPLYTA (Drug) $67,540
- PLEGRIDY (Biological) $63,320
- VNS Therapy (Device) $31,000
- VRAYLAR (Drug) $27,727
- Dayvigo (Drug) $23,900
- HETLIOZ (Drug) $19,877
- NO PRODUCT DISCUSSED (Drug) $15,106
- LATUDA (Drug) $9,642
- VIAGRA (Drug) $7,073
- DASOTRALINE (Drug) $7,001
- Korlym (Drug) $4,500
- BRINTELLIX (Drug) $4,000
- Ajovy (Drug) $3,690
- QUVIVIQ (Drug) $2,505
- Lucemyra/Lofexidine (Drug) $1,500
- NURTEC ODT (Drug) $1,400
- NUPLAZID (Drug) $500.00
- Lucemyra (Drug) $480.00
- None (Drug) $57.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Tampa
Dr. Jamie Fernandez, M.d, M.D
Psychiatry — Payments: $674,462
Psychiatry $674,462
Dr. Kenneth Pages, Md, MD
Psychiatry — Payments: $491,147
Psychiatry $491,147
Dr. Hardeep Singh, Md, MD
Psychiatry — Payments: $403,775
Psychiatry $403,775
Chetan Gandhy, Md, MD
Psychiatry — Payments: $220,445
Psychiatry $220,445
Mr. Brian Gadbois, M.d, M.D
Psychiatry — Payments: $38,094
Psychiatry $38,094
Debra Barnett, Md, MD
Psychiatry — Payments: $37,235
Psychiatry $37,235